Efficacy and CNS results from a randomized subset of the phase 2 SAVANNAH study comparing savolitinib (savo) + osimertinib (osi) combination with savo + placebo (PBO).
Benjamin Levy(Johns Hopkins University), Myung‐Ju Ahn(Sungkyunkwan University), Cheng‐Ta Yang(Shanghai Medical College of Fudan University), Claudia Proto(Fondazione IRCCS Istituto Nazionale dei Tumori), Lyudmila Bazhenova(Memorial Sloan Kettering Cancer Center), Paolo Bironzo(University of Turin), Adrian G. Sacher(Princess Margaret Cancer Centre), Ryan J. Hartmaier(AstraZeneca (United States)), Christina S. Baik(Seattle Cancer Care Alliance), K. Barrett(AstraZeneca (United Kingdom)), Marcello Tiseo(University of Parma), Lecia V. Sequist(Harvard University), Quincy S. Chu, Jonathan W. Riess(University of California Davis Medical Center), I. Igwegbe(AstraZeneca (United States)), Wanning Xu(AstraZeneca (United States)), Filippo de Marinis(Carlo Forlanini Hospital), James C. Yang(National Taiwan University Hospital), Konstantinos Leventakos(Rutgers, The State University of New Jersey)
Cited by 4
Related Papers
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
|The Lancet|2016|4.8k
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Isolation of rare circulating tumour cells in cancer patients by microchip technology
|Nature|2007|3.5k
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k